Home  >  News
News
+ Font Resize -

MorphoSys' licensee Janssen receives Canadian approval for Tremfya to treat plaque psoriasis

Munich, Germany
Wednesday, December 6, 2017, 09:00 Hrs  [IST]

MorphoSys AG, a leader in the field of therapeutic antibodies, announced that its licensee Janssen Inc. (Janssen), previously reported Health Canada approval of Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Tremfya (guselkumab) is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys is eligible to receive royalties on net sales of Tremfya.

Dr. Simon Moroney, chief executive officer of MorphoSys AG, said: "We are very pleased that Tremfya has now been approved in three territories, namely the US, Canada and the European Union. We expect this drug will provide an important treatment option for patients living with moderate-to-severe plaque psoriasis."

Beyond plaque psoriasis, Janssen is studying Tremfya (guselkumab) in a phase 3 psoriatic arthritis development programme.

MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |